Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2022 Jun 12;2(6):2270012. doi: 10.1002/smsc.202270012

Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease

Baisen Zhong 1, Weiyu Peng 2, Shan Du 1, Bingyi Chen 3, Yajuan Feng 1, Xinfeng Hu 1, Qi Lai 1, Shujie Liu 4, Zhong-Wei Zhou 4, Pengfei Fang 5, Yan Wu 6, Feng Gao 7, Huihao Zhou 3, Litao Sun 1,
PMCID: PMC9347789  PMID: 35942318

Abstract

Oridonin Inhibits SARS‐CoV‐2

Oridonin, a natural product extracted from Rabdosia rubescens, possesses a wide range of pharmacological properties, including anti‐inflammatory, anti‐cancer, anti‐microbial, neuroprotection, immunoregulation, etc. In article number 2100124, Baisen Zhong, Litao Sun, and co‐workers demonstrate that Oridonin targets the SARS‐CoV‐2 3CL protease by covalently binding to cysteine145 in its active pocket to exert an anti‐SARS‐CoV‐2 effect, which provides a novel candidate for the treatment of COVID‐19.

graphic file with name SMSC-2-0-g001.jpg


Articles from Small Science are provided here courtesy of Wiley

RESOURCES